SiGA Technologies

SIGA Technologies is a company specializing in the development and commercialization of solutions for serious unmet medical needs and biothreats. Their lead product is tecovirimat, also known as ST-246®, an orally administered antiviral drug that targets orthopoxviruses. While tecovirimat is not yet licensed as safe or effective by the U.S. Food & Drug Administration, it is a novel small-molecule drug that is being delivered to the Strategic National Stockpile under Project BioShield.